Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma

NCT06620926 | Completed

• 1 other identifier: A1997
• Study Type: observational
• Target: 811
• Locations: 1 country
• Sites: 1

Brief Summary

This study looked at a type of brain tumor called astrocytoma and how specific genetic changes like IDH mutations affect patients outcomes. Recent studies found that people with IDH-mutated astrocytomas tend to live longer and have better survival rates compared to those without these mutations. One reason for this is that IDH-mutated tumors usually grow more slowly and are less aggressive. These findings suggest that testing for IDH mutations could help doctors make more personalized treatment plans for patients, which may lead to better results. However, larger studies are needed to confirm these observations. the investigators used the Surveillance, Epidemiology and End Results (SEER) database to obtain the data of 811 patients with grade II/III astrocytoma. The data are publicly available and no consent or ethical approval is needed for this study. The clinicopathological data of patients, including the age, gender, race, IDH status (mutant/wild), astrocytoma type (diffuse/anaplastic), surgery (tumor destruction, Local excision, partial, radical, total gross resection, Surgery), radiation (Beam radiation, Radioactive implants including brachytherapy, Radioisotopes, Combination of beam with implants or isotopes, Radiation, method or source not specified), chemotherapy, vital status, and survival months, were extracted. Patients were sub-grouped according to the IDH type into IDH mutant-type and wild-type. with further stratification according to the treatment modality into three groups: adjuvant chemotherapy, adjuvant radiotherapy, and combined adjuvant chemoradiotherapy. The Observed survival and cause-specific survival were calculated using SEER\*stat software version 8.4.3 and SPSS version 25 was used for survival analysis. Significance was achieved at 0.05.

Conditions

Astrocytoma; Astrocytic Tumors; Astrocytoma of Brain

Keywords

chemotherapy; survival; Astrocytoma; Wild IDH

Outcome Measures

Primary Outcomes (1)

• The 2-year relative survival and 2-year observed survival of grade II/III astrocytoma with IDH mutation

  from Jan, 2018 till Dec, 2020

Secondary Outcomes (1)

• The 2-year relative survival of different treatment with modalities chemo(radio)therapy among both groups: IDH wild type and IDH mutant type astrocytoma

  Jan, 2018 till Dec, 2020

Study Arms (2)

Patients having astrocytoma with IDH mutant-type

Other: IDH mutant-type

Patients having astrocytoma with IDH wild-type

Other: IDH wild-type

Interventions

IDH mutant-type OTHER

The first arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.

Patients having astrocytoma with IDH mutant-type

IDH wild-type OTHER

The second arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.

Patients having astrocytoma with IDH wild-type

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with grade II/III astrocytoma with malignant behavior. The investigators sub-grouped the data according to the IDH mutation type into two groups: IDH wild-type and IDH-mutant type with further stratification according to the treatment modalities the patients received: adjuvant chemotherapy, adjuvant radiotherapy and adjuvant chemoradiotherapy; following any surgical intervention (tumor destruction, Local excision, partial, radical, total gross resection, Surgery)

You may qualify if:

• Patients were selected only if they had astrocytoma with malignant behavior
• Grade II-III astrocytoma
• First primary tumor with sequence 0 or 1
• Had surgical intervention (tumor destruction, Local excision, partial, radical, total gross resection, Surgery)

You may not qualify if:

• unknown survival time
• patients with unknown age
• death certificate only and autopsy only cases

Sponsors & Collaborators

• asmaa salama ibrahim: lead

Study Sites (1)

Suez Canal University

Ismailia, Egypt

Location

Related Publications (1)

• Hamad M, Ali MA, Hamouda E, Hamouda H, Ali N, Al-Shaikh B, Ellaithy A. Impact of IDH mutation and adjuvant chemo(radio)therapy on survival outcome in grade II/III astrocytoma: a retrospective cohort study based on SEER database. Ann Med Surg (Lond). 2025 Mar 20;87(4):1846-1851. doi: 10.1097/MS9.0000000000003172. eCollection 2025 Apr.

  PMID: 40212132 DERIVED

MeSH Terms

Conditions

Astrocytoma

Condition Hierarchy (Ancestors)

Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Officials

• Asmaa Ellaithy, MD

  Suez Canal University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Resident physician of gastroenterology

Study Record Dates

• First Submitted: September 28, 2024
• First Posted: October 1, 2024
• Study Start: January 1, 2018
• Primary Completion: December 30, 2020
• Study Completion: December 30, 2021
• Last Updated: October 29, 2024

Record last verified: 2024-10

Locations

EG (1)